SCHEMBL721427

SCHEMBL721427

Cn1cc(-c2ccnc3cc(-c4ccc(N5CCOCC5)nc4)oc23)cn1

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.49
LRRK2 Q5S007 6/20 0.46
CCNC P24863 1/20 0.45
CDK8 P49336 1/20 0.45
ATR Q13535 1/20 0.44
ATRIP Q8WXE1 1/20 0.44
CNR2 P34972 5/20 0.43
MAPK10 P53779 2/20 0.42
PDE10A Q9Y233 1/20 0.41
MAPK13 O15264 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41
MAPK14 Q16539 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL723621 0.89 MAPK10 (0.51) LRRK2CCNCCDK8ATRATRIP
SCHEMBL724726 0.85 CNR2 (0.50) ATRCNR2PDE10A
SCHEMBL724754 0.83 CNR2 (0.47) LRRK2ATRATRIPCNR2PDE10A
SCHEMBL10268949 0.82 AURKB (0.46) LRRK2CCNCCDK8MAPK10
SCHEMBL722106 0.81 MTOR (0.47) LRRK2CCNCCDK8
SCHEMBL723468 0.80 LRRK2 (0.46) RETLRRK2
SCHEMBL723727 0.77 FYN (0.40) LRRK2
SCHEMBL725506 0.77 KCNH2 (0.43) CCNCCDK8
SCHEMBL15209645 0.76 CCNC (0.39) RETLRRK2CCNCCDK8
SCHEMBL726778 0.76 AURKB (0.44) LRRK2CCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB RET 238/4885LRRK2 787/4885CCNC 2402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.